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Access to Eliciting Doses (ED) for allergens enables advanced food allergen risk assessment. Previously, the full
ED range for 14 allergenic foods, including milk, and recommendations for their use were provided (Houben
et al., 2020). Additional food challenge studies with cow’s milk-allergic patients added 247 data points to the
original dataset. Using the Stacked Model Averaging statistical method for interval-censored data on the 697
individual NOAELs and LOAELs for milk generated an updated full ED distribution. The ED01 and ED05, the
doses at which 1% and 5% of the milk-allergic population would be predicted to experience any objective allergic
reaction, were 0.3 and 3.2 mg milk protein for the discrete and 0.4 mg and 4.3 mg milk protein for the cu
mulative dose distribution, respectively. These values are slightly higher but remain within the 95% confidence
interval of previously published EDs. We recommend using the updated EDs for future characterization of risks of
exposure of milk-allergic individuals to milk protein.
This paper contributes to the discussion on the Reference Dose for milk in the recent Ad hoc Joint FAO/WHO
Expert Consultation on Risk Assessment of Food Allergens. It will also benefit harmonization of food allergen risk
assessment and risk management globally.
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1. Introduction
Labeling of allergenic foods on prepacked foods is crucial in man
aging food allergy by the allergic population as avoidance of the aller
genic food is currently still the best measure for many food allergic
individuals. A list of priority allergenic foods was issued in the General
Standard for the Labelling of Packaged Foods (GSLPF) in 1999, which
included milk and milk products (Codex Alimentarius, 2018). This was
followed by many countries and regulatory bodies implementing
essential laws, regulations, or standards for labeling of “priority aller
gens” to provide clear labeling of priority allergens on prepackaged food
products with the intent to assist allergic consumers with avoidance of
their offending allergenic food source(s) (Yeung and Robert, 2018).
Despite this, cow’s milk is an important cause of unexpected allergic

reactions in the cow’s milk-allergic population, that can be severe and
even fatal (Baseggio Conrado et al., 2021; Blom et al., 2018). Cow’s
milk, further referred to as milk, is ubiquitous in our diet and a major
source of ingredients abundantly used for the production of a variety of
food products. Food allergies are acknowledged as a serious food safety
issue by food industry, but pose considerable challenges for food busi
ness operators (Yeung and Robert, 2018). This is reflected in the large
proportion of product recalls which involve milk or milk derivatives
(Bucchini et al., 2016; Gendel, 2018). Besides issues with mislabeling
products, cross-contact during production can lead to unintended
allergen presence (UAP) in products. The use of precautionary allergen
labeling (PAL) statements that warn consumers about possible UAP are
voluntary and currently not regulated, resulting in a proliferation of
different PAL on products, often unrelated to the actual risk posed to

Abbreviations: DBPCFC, double-blind, placebo controlled food challenge; ED, Eliciting Dose; FAO, Food and Agriculture Organization of the United Nations; WHO,
World Health Organization; LOAEL, lowest observed adverse effect level; NOAEL, no observed adverse effect level; PAL, precautionary allergen label; RD, Reference
Dose; UAP, unintended allergen presence.
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allergic consumers (Blom et al., 2018; DunnGalvin et al., 2019; Yeung
and Robert, 2018).
Since the original drafting of the GSLPF, both allergen risk assess
ment and allergen management have advanced greatly (Houben et al.,
2020). Reference doses (RDs) based on doses predicted to elicit objective
allergic symptoms in no more than 1–5% of the allergic population have
been proposed, including for milk (Houben et al., 2020; Remington
et al., 2020). These RDs can be used for the calculation of Action Levels
to inform the need for PAL on food products, such that PAL would only
be used if the concentration of UAP is above the action level. This
approach is increasingly supported by many stakeholders, including
food business operators, regulatory bodies and patients’ organizations
(DunnGalvin et al., 2019). The full range of a population eliciting dose
distribution for allergens is also valuable, allowing risk assessors to
quantify the risk of an (unintended) allergen concentration in food
products and support decisions with respect to allergen risk manage
ment, for instance, in incidents (explained in detail in Houben et al.
(2020)).
In 2020, the Food and Agriculture Organization of the United Na
tions (FAO) and World Health Organization (WHO) called for experts
and data on the risk assessment of food allergens based on a request from
Codex Alimentarius for scientific advice (https://www.fao.org/3/ca7
121en/ca7121en.pdf). Three expert meetings were held in 2020–2021
to provide scientific advice on various questions relevant to allergen
management and PAL. In the second meeting, Reference Doses (called
RfD by the FAO/WHO) were established using TNO-FARRP threshold
datasets for major allergenic foods, on the basis that this dataset is “the
best described source available, both in terms of content and curation, with
supportive peer-reviewed publications “(FAO/WHO Expert Consultation
et al., 2021). As a starting point, the Expert Consultation considered
ED05 values for priority allergens, i.e., the eliciting dose predicted to
result in objective reactions in no more than 5% of the allergic popu
lation for that allergen, as published in Houben et al. (2020) and Rem
ington et al. (2020) (FAO/WHO Expert Consultation et al., 2021). For
milk and sesame, experts noted that more data are now available for
these allergens, which would enable a refinement of the ED05 values.
Furthermore, a recent publication highlighted the need to extend the
dataset for milk to provide more certainty to the ED05 for this allergen
(Turner et al., 2021a). Therefore, in the present study, we sought
additional eligible studies with data relating to double-blind, placebo-
controlled food challenges (DBPCFC) in cow’s milk-allergic individuals.
Datasets meeting the strict quality criteria as published previously
(Westerhout et al., 2019) were added to the existing threshold dataset
(Remington et al., 2020) and a new analysis was performed using the
stacked Model Averaging Method (Wheeler et al., 2021). Updated
Eliciting Dose values for milk were generated for further use in allergen
risk assessment and for supporting the FAO/WHO expert consultations
in the decision of a Reference Dose for milk.

considered necessary per established clinical consensus. The first
objective symptoms of an allergic response occurring in the patient were
used as the basis for the individual lowest observed adverse effect level
(LOAEL), with the previous dose in the clinical protocol as the individual
no observed adverse effect level (NOAEL). The doses were noted in
terms of mg of total protein from the allergenic food, and were assessed
in terms of discrete and cumulative doses.
For analysis of the data, interval censoring methodology was applied.
Individuals were left-censored if they reacted with objective symptoms
to the first challenge dose. Patients that failed to respond with objective
symptoms to the uppermost challenge dose but did have a clear history
of allergic reactions to milk were right-censored.
The new individual threshold data were combined with the existing
dataset and analyzed with the “Stacked Model Averaging” approach
developed by Wheeler et al. (2021). The R software (https://www.r-pro
ject.org/) and publicly available Stackedsurvpackage (http://doi.
org/10.5281/zenodo.3401471) were used. Details of the methodology
and the applied software can be found in Houben et al. (2020); Rem
ington et al. (2020) and Wheeler et al. (2021). Briefly, the approach
combines five parametric survival distributions (Weibull, Log-Gaussian
(or Log-Normal), Log-Logistic, Generalized Pareto and Log-Laplace (or
Log-Double-Exponential)) and assigns weights to the individual distri
butions based on the goodness of fit to ultimately generate a single
model averaging outcome. This analysis outcome was used to determine
the population Eliciting Doses for the discrete doses and cumulative
doses. The method is based upon a Bayesian stacking methodology and
estimates dose-to-failure based upon Markov chain Monte Carlo
(MCMC) simulation. To minimize variability, the stacked model aver
aging estimation procedure is repeated independently 10 times, and the
mean of 10 ED estimates is used as a central estimate. For the full ED
range the random sampling procedure is truncated at the highest given
dose (discrete or cumulative), based on all of the studies included in the
dataset, as extrapolation beyond the highest given dose would lead to a
change in the model average survival curve, resulting in an over
estimation of lower ED values (Houben et al., 2020).
3. Results
Data were available from two studies which fulfilled the criteria
(Supplementary Table S1), representing a total of 247 new individual
NOAELs and LOAELs from milk allergic patients undergoing a DBPCFC:
83 from the study of Turner et al. (2021b) and 164 received from Na
tional Sagamihara Hospital reported in the publication by Yanagida
et al. (2017). The population age range was under 18 years in both
datasets, as is typical for cow’s milk-allergy given that this food allergy
typically resolves in childhood. Similar to previous studies, these new
studies also included some left- and right-censored individuals. Overall,
the total study population for cow’s milk includes children and adults,
but with young children presenting the highest proportion, with 30% of
data from children aged <5 years of age, 45% aged 5–9 years, 22% aged
10–18 years and 3% > 18 year) (Supplement Fig. S1 for further detail).
Supplementary Table S2 provides the updated table of Remington et al.
(2020) for the sources of data points for milk along with the number of
right- or left-censored subjects, geographic location, first mg protein
dose in the food challenge protocol, and the number of children or
adults. In total, 697 data points were available to model the Eliciting
Dose distribution. Fig. 1 displays as the Stacked Model Averaging result
with the individual distributions. Overall, the weights given to the in
dividual models were similar to the previous milk dataset (Houben et al.,
2020; Remington et al., 2020), with a high weight to the Weibull model
followed by the Log-Laplace (Log-Double-Exponential) model. A slightly
higher weight was observed for the Log-Laplace (Log-Dou
ble-Exponential) model for the updated dataset; however, most of the
weight was still given to the Weibull model. The accompanying
weighing results for the individual models are presented in Supple
mentary Table S3.

2. Data and methods
The dataset for milk published before in Houben et al. (2020) and
Remington et al. (2020) contained 450 individual threshold data for
cow’s milk collected from peer-reviewed publications and unpublished
clinical records. The FAO/WHO Expert Consultation identified six po
tential additional datasets which were subsequently investigated for
availability/accessibility of individual patient data and data quality
according to previously published criteria (Westerhout et al., 2019)
(Supplementary Table S1). This included clear objective stopping
criteria for the allergic reactions, availability of the dosing scheme
(including if/when repeated doses were given), details on the challenge
material, and availability of individual objective threshold doses. Where
needed, authors were contacted to seek this information and address any
data queries. In line with previous publications (Remington et al., 2020;
Westerhout et al., 2019), only data from DBPCFCs were included, except
in the case of infants and very young children where blinding was not
2
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distribution for milk (Houben et al., 2020). Table 1 provides updated
EDs up to the ED50, while Supplementary Table S4 provides the full
updated ED range for milk for use in allergen risk assessment to deter
mine the risk of (unintended) concentrations of milk protein in food
products.
The Bayesian Stacked Parametric Survival methods with Frailty
Components and Interval Censored Failure Times as described by
Wheeler et al. (2021) were used. In this Stacked Model Averaging
technique, five different parametric distributions are modelled,
weighted and combined into a single dose distribution estimate in order
to maximize the predictive accuracy of the calculated ED values. The
predicted Stacked Model Averaging distribution estimate (red line) is
presented with its corresponding 95% posterior predicted failure times
(dashed red lines). The Kaplan-Meier curves for each individual study in
the dataset are also presented (black lines, darker shades indicate studies
with more observations).
Both ED01 and ED05 values have previously been considered in the
framework of establishing Reference Doses for allergen management
and the calculation of action levels (FAO/WHO Expert Consultation
et al., 2021). The updated ED01 and ED05 values were in the same range
as the previously reported values and with overlapping 95% confidence
intervals (Table 2). The effect of including the additional data to the milk
distributions was small (Fig. 2), though the small change in weighing of
the various parametric survival models, with a higher weight to the
Log-Laplace(Log-Double-Exponential) model for the updated dataset
(Supplementary Fig. S2), resulted in a slightly larger confidence interval
in the lower and higher ends of the curve for the updated milk dose
distribution (Table 2 and Fig. 2) compared to the dataset of Houben et al.
(2020).
We also undertook a sensitivity analysis including data from
Rolinck-Werninghaus et al. (2012). These data were omitted from the
final analysis because of uncertainties regarding whether specific chal
lenges were undertaken using DBPCFC or not. As previously published, a
DBPCFC procedure is one of our quality criteria for addition of data to
our database and analysis, with exception of data for the youngest
children (Westerhout et al., 2019). In addition, individual symptom data
was not available, so it was unclear as to whether some of the threshold
doses met the criteria outlined in Westerhout et al. (2019). However,
given the size of this dataset, we evaluated the possible effect of the
inclusion of these additional data on the ED values. For this sub-analysis,
including the data from Rolinck-Werninghaus et al. (2012), there were a
total of 1002 data points, resulting in an ED01 of 0.2 mg (95% CI
0.1–0.3) of total milk protein and an ED05 of 2.1 mg (95% CI 1.2–3.8) of
total milk protein for the discrete dose distribution. For the cumulative
dose distribution, the estimated ED01 was 0.3 mg (95% CI 0.2–0.5), and
the ED05 was 2.9 mg (95% CI 1.6–5.4) of total milk protein. Therefore,
the inclusion of data from Rolinck-Werninghaus et al. (2012) resulted in
slightly lower estimates for ED01 and ED05, but the resulting ED01 and
ED05 values were almost equal to those presented in Remington et al.
(2020) and (Houben et al. (2020) (Supplementary Fig. S3).

Fig. 1. Dose distribution modeling for cow’s milk expressed as discrete dose
(A) or the cumulative dose (B) of mg milk protein.

The 55% increase of the total size of the milk dataset resulted in small
increases of the ED values compared to the previously published data on
the ED01 and ED05 (Remington et al., 2020) and the full range
Table 1
The ED01 to ED10, ED15, ED20, ED25, and ED50 values from the model aver
aged population threshold dose distributions for cow’s milk (n = 697), based on
discrete (A) and cumulative (B) dose datasets. The 95% confidence interval is
represented by the lower confidence interval (LCI) and the upper confidence
interval (UCI).
A. Discrete dose dataset

B. Cumulative dose dataset

ED

mga)

LCI

UCI

ED

mga)

LCI

UCI

ED01.0
ED02.0
ED03.0
ED04.0
ED05.0
ED06.0
ED07.0
ED08.0
ED09.0
ED10.0
ED15.0
ED20.0
ED25.0
ED50.0

0.3
0.8
1.5
2.3
3.2
4.2
5.2
6.4
7.6
9.0
16.7
26.3
37.9
133

0.2
0.5
0.8
1.3
1.8
2.3
3.0
3.6
4.4
5.1
9.7
15.5
22.4
79.3

0.7
1.8
3.1
4.7
6.4
8.3
10.3
12.4
14.7
17.1
31.0
47.8
67.7
229

ED01.0
ED02.0
ED03.0
ED04.0
ED05.0
ED06.0
ED07.0
ED08.0
ED09.0
ED10.0
ED15.0
ED20.0
ED25.0
ED50.0

0.4
1.1
2.0
3.1
4.3
5.8
7.3
9.0
10.8
12.8
24.3
39.0
56.8
207

0.3
0.6
1.0
1.7
2.4
3.2
4.0
5.0
6.0
7.1
13.8
22.4
32.8
120

0.9
2.4
4.3
6.5
9.0
11.8
14.8
18.0
21.5
25.1
46.3
72.5
104
364

a

4. Discussion
Population EDs values are valuable for use in allergen risk assess
ment and for the derivation of reference doses to inform the decision for
the use of PAL. Milk protein is an important cause of accidental allergic
reactions due to unintended presence in food products with or without a
PAL statement (Blom et al., 2018). Milk is also a major cause of
anaphylaxis and even death globally (reviewed by Baseggio Conrado
et al. (2021). An internationally-harmonized Reference Dose to inform
the decision to either or not apply a PAL statement, as proposed by the
FAO/WHO expert consultation (FAO/WHO Expert Consultation et al.,
2021), would represent a step forwards in improving allergen risk
management with respect to cow’s milk, and importantly, offer safer
food choices for allergic consumers.
The addition of 247 new data points from DBPCFC in cow’s milk-

ED values are expressed in mg total milk protein.
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Table 2
Comparison of the updated ED01 and ED05 for cow’s milk with the previously reported EDs. The ED values are expressed in mg total milk protein,
along with the 95% confidence interval (95% CI).
Discrete

Cumulative

Dataset

No of individuals

ED01 (95% CI)

ED05 (95% CI)

ED01 (95% CI)

ED05 (95% CI)

Updated milk ED distribution

697

0.3 (0.2–0.7)

3.2 (1.8–6.4)

0.4 (0.3–0.9)

4.3 (2.4–9.0)

Milk ED distribution (Houben et al., 2020)

450

0.2 (0.1–0.5)

2.4 (1.3–5.0)

0.3 (0.2–0.6)

3.1 (1.6–6.6)

difference in the weighing of the models, which slightly changed the
lower and higher end of the modelled distributions and caused a slightly
larger confidence interval despite the larger number of datapoints. This
is the result of the type of datasets added. The sensitivity analysis
showed that adding the dataset of Rolinck-Werninghaus et al. (2012),
reduced the confidence interval. With every new dataset added, there
will be some change in the exact ED values and confidence intervals, but
our present analysis shows that, overall, the population ED distribution
for milk remains stable. The small variability would be predicted to have
no relevant effect for the estimation of the risk of allergen levels in food
products. The addition of the dataset of Rolinck-Werninghaus et al.
(2012) in our sub-analysis shifted the discrete ED05 back to 2.1 mg milk
protein, very close to the discrete ED05 value of 2.4 mg milk protein
published previously (Houben et al., 2020; Remington et al., 2020), but
all EDs remained within the 95% confidence interval of the updated and
the previously published population ED distribution (Houben et al.,
2020).
The present study was limited to including just two additional
studies, though a substantial number of new data points were added.
Additional food challenges – both DBPCFC and open challenges to cow’s
milk – have been reported elsewhere both in publications and unpub
lished data, but these studies did not meet our quality criteria (West
erhout et al., 2019) or individual challenge data were not available for
inclusion. To avoid confusion and potentially small differences in
calculated risks among risk assessors and managers worldwide, updating
any threshold dose distribution should have a clear rationale. For
example, if uncertainty can be reduced through the inclusion of new
datapoints.
Various ED05 values have been published for milk in different
studies, varying in value depending on the dataset (size, possible patient
selection, dosing scheme) and methodology used to model the data for
estimating an ED value (in mg milk protein) used (Klein-Entink et al.,
2014; Remington et al., 2020; Wheeler et al., 2021). As indicated by
Turner et al. (2021a), these ED05 estimates can vary from 0.5 to 13.9 mg
milk protein.
A single-dose challenge study recently queried whether the previous
ED05 estimates for milk might be an overestimate (Turner et al., 2021a),
a concern also raised by Rolinck-Werninghaus et al. (2012). The single
dose study with milk by Turner et al., (2021a) investigated the reaction
frequency at a dose of 0.5 mg milk protein in a population of 172 milk
allergic patients. The reaction frequency found in the study indicated
that the 0.5 mg dose tested might comply with an ED05, but could reflect
an ED value between ED3.7 to ED11.9. According to the data published
by Houben et al. (2020) a 0.5 mg dose of milk protein would reflect an
ED value between the ED0.9 and ED3.0, based on the confidence in
tervals of the discrete and cumulative dose distribution datasets. Turner
et al., (2021a) suggested that additional, larger challenge data sets are
needed to provide more precision to the population dose-distribution
modelling around lower ED values. Our current study provides such
dataset extension by incorporating additional data, which included
participants from Turner et al. (2021a), as well as sensitivity analysis on
including even more datapoints to the existing large milk threshold
dataset. This sensitivity analysis included data from Rolinck-Werning
haus et al. (2012). Based on the confidence intervals of the extended
discrete and cumulative dose distribution datasets (see Supplementary

Fig. 2. ED curves from the model average population threshold dose distri
bution for milk (Houben et al., 2020) (black) and the updated milk distribution
with the 95% confidence interval (red). (A) Discrete and (B) Cumulative dose
dataset. (For interpretation of the references to colour in this figure legend, the
reader is referred to the Web version of this article.)

allergic patients to the existing TNO-FARRP dataset for milk (n = 450)
did not result in significantly different ED01 and ED05 values, or in a
significant shift in the overall population ED distribution for milkallergic individuals. Previous research predicted that expansions of
already large datasets used to calculate EDs will unlikely result in sig
nificant changes in the EDs (Klein Entink et al., 2014; Remington et al.,
2020). A factor that may contribute to the small variation in modelling
results of the final EDs can be the use of a protocol starting at relatively
higher doses, such as with the study of Yanagida et al. (2017). In our
current analysis, addition of the two new datasets resulted in a small
4
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Table S4), a 0.5 mg dose of milk protein reflects an ED value between
ED0.8 and ED2.0 and indeed shows a more narrow interval and thus
higher precision compared to the ED-estimate of a 0.5 mg dose based on
Houben et al., (2020). Both Houben et al., 2020 and our current study
indicate a slightly lower ED value for the 0.5 mg dose compared to the
results of Turner et al., (2021a). This might well be associated with the
substantial smaller dataset used by Turner et al., (2021a) and possibly an
associated different range and variability in patient sensitivity, but also
with the study conduct. The single-dose challenge study conducted by
Turner et al., (2021a) aimed to test whether a dose of 0.5 mg milk
protein could comply with an ED05 and did not falsify this hypothesis, as
any outcome between an ED3.7 and ED11.9 confirmed the hypothesis. It
should be noted however that such study using only one single dose is
not suitable to model eliciting dose distributions and estimate ED values.
For the latter purpose, full eliciting dose distributions based on multiple
dose levels as presented in our current study are needed.
Our study showed that additions of new data to the already large
dataset used by Houben et al. (2020) only marginally changed the
population ED values and provided assurance that the ED-estimates
from our dataset are robust. The overall dataset has a broad
age-distribution and the results of this study gives assurance that the
estimated ED01 and ED05 for milk generated in this and our previous
study (Houben et al., 2020) are sufficiently robust for use in risk
assessment and management decisions for the (unintended) presence of
milk protein in food products.
The present study provides the updated full range of ED values for
milk protein (Supplementary Table S4) that we now recommend to use
for risk assessment and management purposes. For other priority aller
genic foods, readers are referred to the original publications of Houben
et al. (2020) and Remington et al. (2020).

TNO Research Cooperation Funds, Netherlands, and the Food Allergy
Research and Resource Program (FARRP) of the University of NebraskaLincoln, USA.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.fct.2022.113381.
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